GO:1990930 mRNA N1-methyladenosine dioxygenase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1990930 describes the enzymatic activity that removes the N1-methyl group from m1A in RNA, using 2-oxoglutarate and releasing formaldehyde.
• The best-characterized human enzyme carrying this activity is ALKBH3, an Fe(II)/2-oxoglutarate-dependent dioxygenase.
• ALKBH3-mediated m1A demethylation is structurally resolved and requires a specific substrate-binding pocket and metal cofactor.
• m1A modification and its regulators, including ALKBH3, influence RNA stability, translation and cellular fate decisions.
• Dysregulation of m1A demethylation has been linked to cancer biology, including multiple myeloma, and to diabetic microvasculopathy.
• CRISPR knockout, point-mutation, knock-in and overexpression models are key tools to dissect the causal roles of m1A dioxygenase activity.
Description
GO:1990930, mRNA N1-methyladenosine dioxygenase activity, is a molecular function term that defines the oxidative demethylation of N1-methyladenosine (m1A) in RNA. This activity removes the methyl group from the N1 position of adenosine, converting m1A back to unmodified adenosine, and is coupled to the decarboxylation of 2-oxoglutarate with release of the oxidized methyl group as formaldehyde. The reaction is catalyzed by Fe(II)/2-oxoglutarate-dependent dioxygenases, and in humans the enzyme ALKBH3 is a principal mediator of this activity. Because m1A is a reversible RNA modification, the balance between its addition and removal is critical for post-transcriptional gene regulation. Researchers study GO:1990930 to understand how dynamic m1A demethylation shapes RNA fate, translation and cellular phenotypes in health and disease.
mRNA N1-methyladenosine dioxygenase activity At A Glance
| GO ID | GO:1990930 |
|---|---|
| GO term | mRNA N1-methyladenosine dioxygenase activity |
| Ontology | molecular_function |
| Synonym | RNA N1-methyladenosine dioxygenase activity; RNA N(1)-methyladenosine dioxygenase activity |
| Major function | Oxidative demethylation of m1A in RNA, coupled to 2-oxoglutarate decarboxylation and formaldehyde release |
| Cofactor | Fe(II) and 2-oxoglutarate (2-OG) |
| Representative human enzyme | ALKBH3 |
| Substrate | N1-methyladenosine (m1A) in RNA |
| Reaction byproducts | Formaldehyde, succinate, CO2 |
What Is GO:1990930?
In simple terms, GO:1990930 is the activity that erases a specific chemical mark (m1A) from RNA. The official definition states that this activity catalyzes the oxidative demethylation of N1-methyladenosine RNA, with concomitant decarboxylation of 2-oxoglutarate, releasing the oxidized methyl group as formaldehyde. This is a dioxygenase-type reaction that requires molecular oxygen and a metal cofactor, and it directly reverses the m1A modification on RNA substrates.
Why Is mRNA N1-methyladenosine dioxygenase activity Important in Cell Biology?
GO:1990930 is important because it controls the reversible removal of m1A, a modification that affects RNA structure, stability and translation. The activity of m1A dioxygenases such as ALKBH3 influences gene expression programs that are critical for cell growth, stress responses and differentiation. In disease contexts, altered m1A demethylation has been associated with cancer progression and vascular pathology, making this activity a potential therapeutic target.
• Regulates RNA stability and translation by removing m1A marks.
• Influences cell fate decisions, including endothelial cell identity and neovascularization.
• Linked to cancer biology, with m1A regulators showing prognostic value in multiple myeloma.
• Contributes to diabetic microvasculopathy through ALKBH3-dependent mechanisms.
• Provides a druggable target: ALKBH3 inhibition can normalize pathological neovessels.
• Essential for understanding epitranscriptomic dynamics and post-transcriptional control.
• Enables mechanistic studies of Fe(II)/2-OG dioxygenase chemistry in RNA modification.
• Supports development of CRISPR models to test causality of m1A regulators.
Molecular Mechanism of mRNA N1-methyladenosine dioxygenase activity
Substrate recognition and binding
In simple terms: The enzyme must first find and hold the m1A-marked RNA.
ALKBH3 recognizes m1A-containing RNA through a specific binding pocket that accommodates the methylated adenosine. Structural studies show that the enzyme makes key contacts with the RNA backbone and the modified base, ensuring selectivity for m1A over unmodified adenosine. This substrate recognition step is essential for the subsequent oxidative demethylation reaction.
Catalytic oxidative demethylation
In simple terms: The enzyme uses oxygen and a cofactor to remove the methyl group.
The catalytic core of ALKBH3 contains an Fe(II) ion coordinated by conserved residues, and 2-oxoglutarate (2-OG) acts as a co-substrate. In the presence of molecular oxygen, the enzyme hydroxylates the methyl group on m1A, leading to its release as formaldehyde. This reaction is coupled to the decarboxylation of 2-OG to succinate, completing the dioxygenase cycle.
Cofactor requirements and metal coordination
In simple terms: The enzyme needs iron and 2-OG to work.
ALKBH3 activity strictly depends on Fe(II) and 2-OG. The metal ion is held in place by a conserved His-Asp-His triad, and 2-OG binds in a pocket adjacent to the metal. Mutations that disrupt metal or 2-OG binding abolish demethylation activity, confirming their essential roles.
Product release and RNA fate
In simple terms: After demethylation, the RNA is released and can be translated or degraded.
Following demethylation, the unmodified adenosine remains in the RNA, and the enzyme releases formaldehyde, succinate and CO2. The removal of m1A can alter RNA secondary structure and protein interactions, thereby affecting translation efficiency and stability. This links the catalytic activity directly to downstream post-transcriptional regulation.
Key Genes Involved in GO:1990930 mRNA N1-methyladenosine dioxygenase activity
The following genes and proteins are directly or indirectly involved in m1A dioxygenase activity and its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ALKBH3 | Primary human m1A dioxygenase that removes m1A from RNA | Central enzyme for mechanistic and structural studies |
| ALKBH2 | Related AlkB family dioxygenase with different substrate specificity | Comparative studies of dioxygenase specificity |
| FTO | Fe(II)/2-OG dioxygenase with demethylase activity on other RNA modifications | Context for understanding dioxygenase family diversity |
| ALKBH5 | m6A demethylase, not m1A dioxygenase | Distinguishing m1A from m6A regulation |
| METTL3 | m6A writer, not directly m1A | Contrasting writer/eraser functions in epitranscriptomics |
| METTL14 | m6A writer complex component | Reference for RNA modification machinery |
| WTAP | m6A writer complex component | Context for modification complex assembly |
| YTHDF1 | m6A reader, not m1A-specific | Illustrates reader-mediated downstream effects |
| YTHDF2 | m6A reader involved in RNA stability | Comparison of reader pathways |
| IGF2BP1 | RNA-binding protein affecting stability | Potential downstream effector of m1A changes |
| HNRNPA2B1 | RNA-binding protein with m6A/m1A-related functions | Candidate for m1A-dependent splicing regulation |
| ELAVL1 | RNA stability regulator | Downstream RNA fate factor |
| VEGFA | Angiogenesis regulator affected by ALKBH3 inhibition | Model for vascular phenotypes |
| CDH5 | Endothelial junction protein | Marker of endothelial fate changes |
| PECAM1 | Endothelial cell marker | Used to assess neovessel normalization |
| ACTB | Housekeeping control | Reference gene in expression studies |
| GAPDH | Housekeeping control | Reference gene in expression studies |
How Is mRNA N1-methyladenosine dioxygenase activity Regulated?
The activity of m1A dioxygenases is regulated at multiple levels. ALKBH3 expression and activity can be influenced by cellular stress and metabolic state, given its dependence on 2-oxoglutarate and Fe(II). In disease models, inhibition of ALKBH3 alters endothelial gene expression programs, suggesting that its activity is integrated with signaling pathways controlling cell fate. Additionally, m1A regulators show coordinated expression patterns in cancer, implying transcriptional and post-transcriptional control of the modification machinery.
mRNA N1-methyladenosine dioxygenase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ALKBH3 | Diabetic microvasculopathy | Endothelial cell knockout and overexpression |
| ALKBH3 | Cancer / multiple myeloma | Myeloma cell lines with ALKBH3 knockdown |
| ALKBH3 | RNA modification dysregulation | Recombinant protein assays and structural studies |
| VEGFA | Angiogenesis | Endothelial tube formation assays |
| CDH5 | Endothelial barrier function | Knockout models for junction integrity |
Cancer and multiple myeloma
m1A regulators, including components related to dioxygenase activity, show altered expression in multiple myeloma and are associated with prognostic signatures. The balance of m1A modification affects RNA stability and translation of oncogenic transcripts, contributing to tumor cell survival. Targeting m1A demethylation is therefore being explored as a therapeutic strategy.
Diabetic microvasculopathy
ALKBH3 inhibition normalizes neovessels by reprogramming endothelial fate in diabetic microvasculopathy. This suggests that m1A dioxygenase activity contributes to pathological angiogenesis and that its modulation can restore vascular function. The study highlights ALKBH3 as a potential target for diabetic vascular complications.
Epitranscriptomic dysregulation in disease
Because m1A affects RNA structure and protein interactions, dysregulated demethylation can broadly impact gene expression programs. Structural insights into ALKBH3 provide a basis for understanding how mutations or altered activity may contribute to disease. This knowledge supports the development of small-molecule modulators of m1A dioxygenases.
From mRNA N1-methyladenosine dioxygenase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does ALKBH3 loss alter m1A levels? | ALKBH3 knockout cell lines |
| Which residues are required for catalysis? | Point-mutation knock-in of catalytic residues |
| How does m1A demethylation affect RNA stability? | Knock-in of tagged ALKBH3 for RNA immunoprecipitation |
| Can ALKBH3 overexpression reprogram endothelial cells? | Overexpression in endothelial cells |
| What are the downstream targets of m1A demethylation? | Knockout combined with RNA-seq |
| Is ALKBH3 inhibition sufficient to normalize neovessels? | Inhibitor treatment in diabetic models |
How to Study the mRNA N1-methyladenosine dioxygenase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| m1A-seq | Global m1A modification sites | Mapping changes upon ALKBH3 knockout |
| RNA-seq | Transcript abundance and stability | Identifying downstream targets |
| In vitro demethylation assay | Enzymatic activity of ALKBH3 | Testing catalytic mutants |
| Crystallography | Three-dimensional structure | Understanding substrate binding |
| CRISPR knockout | Loss-of-function phenotypes | Causal gene validation |
| CRISPR knock-in | Tagged or mutant protein expression | Localization and interaction studies |
| Proteomics | Protein interactions | Identifying regulatory complexes |
| Endothelial tube formation | Angiogenic capacity | Testing ALKBH3 inhibitors |
RNA sequencing and m1A mapping
RNA-seq and m1A-specific mapping techniques can quantify changes in m1A levels upon modulation of dioxygenase activity. These methods identify transcripts whose stability or translation is affected by ALKBH3.
Structural and biochemical assays
Recombinant ALKBH3 and its mutants can be used in in vitro demethylation assays to measure catalytic activity and cofactor requirements. Structural studies provide atomic-level insights into substrate recognition and catalysis.
CRISPR-based functional genomics
CRISPR knockout and knock-in models enable causal testing of ALKBH3 and related genes in cellular phenotypes. Pooled screens can identify modifiers of m1A dioxygenase activity.
Proteomics and interactomics
Affinity purification of tagged ALKBH3 followed by mass spectrometry can reveal interacting proteins and RNA partners. This helps define the broader m1A regulatory network.
How CRISPR Can Be Used to Study GO:1990930 mRNA N1-methyladenosine dioxygenase activity
Knockout
CRISPR knockout of ALKBH3 can eliminate m1A dioxygenase activity, leading to elevated m1A levels and altered RNA fate. Such models are used to test the requirement of ALKBH3 for endothelial cell function and cancer cell growth.
Point Mutation
Point mutations in the catalytic domain of ALKBH3 can abolish Fe(II) or 2-OG binding, providing a clean way to separate enzymatic activity from scaffolding functions. These mutants are valuable for rescue experiments.
Knock-in
Knock-in of epitope-tagged ALKBH3 allows for RNA immunoprecipitation and localization studies without altering endogenous regulation. This approach helps identify direct RNA targets of m1A demethylation.
Overexpression
Overexpression of wild-type or mutant ALKBH3 can reveal gain-of-function phenotypes, such as changes in neovascularization or tumor growth. It is also useful for producing recombinant protein for biochemical assays.
How EDITGENE Supports mRNA N1-methyladenosine dioxygenase activity Research
Researchers studying mRNA N1-methyladenosine dioxygenase activity-related genes often need to determine whether a candidate gene is causally involved in m1A regulation, RNA fate and disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR services to accelerate this discovery process.
Contact EDITGENE today to design your custom CRISPR model for mRNA N1-methyladenosine dioxygenase activity research.
Frequently Asked Questions About mRNA N1-methyladenosine dioxygenase activity
What is mRNA N1-methyladenosine dioxygenase activity?
It is the enzymatic activity that removes the m1A modification from RNA, using 2-oxoglutarate and releasing formaldehyde.
What genes are involved in mRNA N1-methyladenosine dioxygenase activity?
The primary human gene is ALKBH3, which encodes an Fe(II)/2-oxoglutarate-dependent dioxygenase.
What is the GO ID for mRNA N1-methyladenosine dioxygenase activity?
The GO ID is GO:1990930.
Which enzyme removes m1A from RNA?
ALKBH3 is the main human enzyme that catalyzes m1A demethylation.
What cofactors are required for m1A dioxygenase activity?
Fe(II) and 2-oxoglutarate are required cofactors.
How is m1A dioxygenase activity linked to cancer?
m1A regulators show altered expression and prognostic value in cancers such as multiple myeloma.
Can ALKBH3 inhibition affect blood vessels?
Yes, ALKBH3 inhibition normalizes neovessels in diabetic microvasculopathy models.
What methods are used to study m1A demethylation?
m1A-seq, RNA-seq, in vitro demethylation assays and structural studies are commonly used.
What is the difference between m1A and m6A?
m1A is methylation at the N1 position of adenosine, while m6A is at the N6 position; they are removed by different enzymes.
How can CRISPR help study m1A dioxygenase activity?
CRISPR knockout, knock-in and point mutations allow causal testing of ALKBH3 function in cells and disease models.
Conclusion
GO:1990930, mRNA N1-methyladenosine dioxygenase activity, represents a key enzymatic function in the epitranscriptome, with ALKBH3 as its principal human mediator. Its ability to reverse m1A marks influences RNA fate and has been linked to cancer and vascular disease. Continued research using CRISPR models and advanced sequencing will further clarify its therapeutic potential.
References
- 1. Zhang YC et al.. 2026. ALKBH3 inhibition normalizes neovessels by reprogramming endothelial fate in diabetic microvasculopathy.. Proc Natl Acad Sci U S A 123(34):e2602779123 PMID: 42627826
- 2. Zhang L et al.. 2024. The Molecular Basis of Human ALKBH3 Mediated RNA N(1) -methyladenosine (m(1) A) Demethylation.. Angew Chem Int Ed Engl 63(7):e202313900 PMID: 38158383
- 3. Fu J et al.. 2025. m1A regulator‑mediated methylation modifications and gene signatures and their prognostic value in multiple myeloma.. Exp Ther Med 29(1):18 PMID: 39624591
